Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Combination antibiotics show promise against Drug-Resistant pneumonia

NCT ID NCT07671755

Disease control Sponsor: Shaheed Mohtarma Benazir Bhutto Institue of Trauma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two antibiotic treatments for ventilator-associated pneumonia caused by a multidrug-resistant bacteria. Researchers compared giving patients just colistin versus colistin plus cefoperazone-sulbactam. They measured how well patients improved clinically and on chest X-rays. The trial included 80 adults with this specific infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
colistin and cefoperazone-sulbactam
What this could lead to
If the combination works better, it could offer a more effective treatment option for this hard-to-treat lung infection.
What could go wrong
This is a small, completed study with only 80 participants, so results may not apply widely. The drugs can cause kidney or liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Feb 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a diagnosis of VAP due to A. baumannii Exclusion Criteria: * patients who had polymicrobial VAP * Patients with pre-existing severe renal failure and/or abnormal liver function tests * Patients allergic to colistin or cefoperazone-sulbactam

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical response are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical response Radiological response

Contacts and locations

Locations

  • Shaheed Mohtarma Benazir Bhutto Institue of Trauma

    Karachi, Pakistan